Clinical Trial Update: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase Ib trial evaluating HS-10370 in combination with other anti-cancer therapies for KRAS G12C-mutant advanced solid tumors, including non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HS-10370

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors | Phase 1 | Status: NOT_YET_RECRUITING